Bristol Myers Squibb Company Profile

✉ Email this page to a colleague

BRISTOL MYERS SQUIBB has seventy approved drugs.

There are thirteen US patents protecting BRISTOL MYERS SQUIBB drugs.

There are five hundred and ninety-six patent family members on BRISTOL MYERS SQUIBB drugs in fifty-one countries and one hundred and forty-three supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	TESLAC	testolactone	TABLET;ORAL	016118-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Bristol Myers Squibb	VIDEX	didanosine	FOR SOLUTION;ORAL	020155-004	Oct 9, 1991		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Bristol Myers Squibb	AZACTAM	aztreonam	INJECTABLE;INJECTION	050580-002	Dec 31, 1986	AP	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	SUSTIVA	efavirenz	TABLET;ORAL	021360-002	Feb 1, 2002	5,519,021*PED	⤷ Try a Trial
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-004	May 30, 2008	7,125,875*PED	⤷ Try a Trial
Bristol Myers Squibb	VIDEX	didanosine	TABLET, CHEWABLE;ORAL	020154-002	Oct 9, 1991	4,861,759*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-16
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Capsules	100 mg and 150 mg	➤ Subscribe	2010-03-19
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2009-04-09
➤ Subscribe	Nasal Spray	4 mg/spray	➤ Subscribe	2016-07-15
➤ Subscribe	Tablets	2.5 mg and 5 mg	➤ Subscribe	2016-12-28
➤ Subscribe	Tablets	20 mg, 50 mg, 70 mg and 100 mg	➤ Subscribe	2010-06-28
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-17
➤ Subscribe	Delayed-release Capsules	200 mg, 250 mg and 400 mg	➤ Subscribe	2004-06-01
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30
➤ Subscribe	Capsules	300 mg	➤ Subscribe	2009-07-20
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2010-02-16
➤ Subscribe	Capsules	50 mg, 100 mg and 200 mg	➤ Subscribe	2016-11-03
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-06-14
➤ Subscribe	Tablets	30 mg	➤ Subscribe	2005-06-01

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1427415	11C0042	France	⤷ Try a Trial	PRODUCT NAME: APIXABAN, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/691/001 20110520
1427415	C01427415/01	Switzerland	⤷ Try a Trial	FORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY, US
1427415	C 2011 008	Romania	⤷ Try a Trial	PRODUCT NAME: APIXABANSI SARURI ACCEPTABILE FARMACEUTIC ALE ACESTUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/691/001, RO EU/1/11/691/002, RO EU/1/11/691/003, RO EU/1/11/691/004, RO EU/1/11/691/005; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/691/001, EU/1/11/691/002, EU/1/11/691/003, EU/1/11/691/004, EU/1/11/691/005; DATE OF FIRST AUTHORISATION IN EEA: 20110518
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.